Applied’s lead candidate is a selective aldose reductase inhibitor called govorestat, an asset that failed to hit primary endpoints in late-stage trials for a progressive neuromuscular disease called ...

Under the terms of the merger agreement, Cycle will commence a tender offer to acquire all of the outstanding shares of Applied common stock for a per share price of $0.088 per share in cash payable ...

With the fast developing technology, the complexity of design is increasing day by day. To meet lower technology challenges and to achieve good silicon yield, SOC design flows have been enhanced and ...

In the Design Cycle I will be focusing on the devices, tools, technologies and techniques that will help you get your job done. If I see an interesting tool, I'll let you know, same for products, ...